Enterprise Value

1.398B

Cash

355.9M

Avg Qtr Burn

-59.76M

Short % of Float

7.70%

Insider Ownership

7.98%

Institutional Own.

82.78%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Roxadustat (ROW) Details
Chronic kidney disease, Anemia

Approved

Quarterly sales

Roxadustat (U.S.) Details
Chronic kidney disease, Anemia

sNDA

Submission

Pamrevlumab Details
Pancreatic cancer, Cancer

Big Mover™

Susp. Mover™

Phase 3

Data readout

Pamrevlumab Details
Idiopathic pulmonary fibrosis

Big Mover™

Susp. Mover™

Phase 3

Data readout

Roxadustat Details
Chemotherapy Induced Anemia

Phase 3

Data readout

Pamrevlumab Details
Duchenne muscular dystrophy

Big Mover™

Susp. Mover™

Phase 3

Data readout

Roxadustat Details
Myelodysplastic syndrome, Anemia

Phase 3

Update

Pamrevlumab Details
COVID-19, Infectious disease

Failed

Discontinued